Related Experiment Video
Updated: Aug 11, 2026
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children with haematological malignancies
1Department of Paediatric Haematology and Oncology, Hospital Niño Jesús, Autonomous University of Madrid, Spain.
Insights
Allogeneic peripheral blood progenitor cell (PBPC) transplantation using G-CSF mobilized stem cells from HLA-identical siblings is effective in children with hematological malignancies. This method shows successful engraftment and may be an alternative to bone marrow transplantation.
Area of Science:
- Pediatric Hematology
- Hematopoietic Stem Cell Transplantation
- Oncology
Background:
- Hematological malignancies in children often require intensive treatment.
- Allogeneic stem cell transplantation is a curative option.
- Peripheral blood progenitor cell (PBPC) transplantation is an alternative to bone marrow transplantation (BMT).
Purpose of the Study:
- To evaluate the efficacy and safety of allogeneic PBPC transplantation in children with hematological malignancies.
- To assess engraftment kinetics and graft-versus-host disease (GVHD) incidence.
- To compare PBPC transplantation with traditional BMT in pediatric patients.
Main Methods:
- Five children with hematological malignancies received allogeneic PBPC transplants.
- PBPCs were harvested from HLA-identical sibling donors mobilized with G-CSF.
- Apheresis was performed using a Cobe Spectra device, and allografts were cryopreserved.
- Infused cell doses (CD34+ and CD3+) and engraftment times were recorded.
Main Results:
- All patients achieved successful engraftment.
- Median time to neutrophil engraftment was 15 days; median time to platelet engraftment was 14 days.
- The incidence of severe acute graft-versus-host disease was 20%.
Conclusions:
- Allogeneic PBPC transplantation is a feasible and effective treatment for pediatric hematological malignancies.
- PBPC transplantation demonstrates comparable engraftment to BMT with manageable GVHD.
- This approach offers a potential alternative to bone marrow transplantation in children.
Abstract:
We report on five children with haematological malignancies who underwent allogeneic peripheral blood progenitor cell (PBPC) transplantation. PBPC were harvested from HLA-identical sibling donors after G-CSF (10 micrograms/kg/d s.c.) mobilization. Aphereses were carried out on day 5 after G-CSF using a Cobe Spectra blood cell separator. All PBPC allografts were cryopreserved before transplantation. The median of CD34+ cells and CD3+ cells infused were 14.1 x 10(6)/kg recipient body weight (range 4.92-22.3) and 2.40 x 10(8)/kg recipient body weight (range 0.54 4.82), respectively. Engraftment occurred in all cases. The median time to a neutrophil count > 0.5 x 10(9)/l and a platelet count > 20 x 10(9)/l were 15 and 14 d, respectively. The incidence of severe acute graft-versus-host disease was 20%. These data suggest that allogeneic PBPC transplantation might be an alternative to bone marrow transplantation in children.
More Related Videos
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...